• Publications
  • Influence
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.
IMPORTANCE Carfilzomib-lenalidomide-dexamethasone therapy yields deep responses in patients with newly diagnosed multiple myeloma (NDMM). It is important to gain an understanding of thisExpand
  • 179
  • 4
  • Open Access
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases.
Flow cytometric (FC) enumeration of abnormal plasma cells (APCs) for diagnosis and prognostication of plasma cell dyscrasias (PCD) is challenging. We studied antigen expression in normal plasma cellsExpand
  • 50
  • 4
Phase II Clinical and Correlative Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRD-R) Induces High Rates Of MRD Negativity In Newly Diagnosed
Background An irreversible proteasome inhibitor with decreased peripheral neuropathy compared to bortezomib, Carfilzomib (Cz) has potent anti-MM effects resulting in deep clinical responses andExpand
  • 37
  • 4
  • Open Access
Chemotherapy-induced nausea and vomiting: an overview and comparison of three consensus guidelines
Chemotherapy-induced nausea and vomiting (CINV) remains one of the most debilitating toxicities associated with cancer treatment. In recent decades, significant strides have been made in ourExpand
  • 16
  • 3
Bendamustine: something old, something new
BackgroundBendamustine (Treanda, Ribomustin) is a water-soluble, bifunctional chemotherapeutic agent that also has potential antimetabolite properties and only partial cross-resistance with otherExpand
  • 49
  • 2
Myonecrosis in Sickle Cell Anemia—Overlooked and Underdiagnosed
Medical literature detailing muscular complications of sickle cell anemia is sparse and limited to a few case-reports. Features consistent with myositis and myonecrosis are often overlooked andExpand
  • 21
  • 2
  • Open Access
Hyperammonemic encephalopathy: a rare presentation of fibrolamellar hepatocellular carcinoma.
Fibrolamellar carcinoma (FLC) is a rare malignant hepatocellular tumor of unknown etiology, arising almost exclusively from noninfected, noncirrhotic liver of young adults. FLC has traditionally beenExpand
  • 25
  • 2
Altered cytokine and chemokine profiles in multiple myeloma and its precursor disease.
Currently, no reliable biomarkers are available to predict transformation from smoldering myeloma (SMM) to multiple myeloma (MM). Using an ultrasensitive enzyme-linked immunosorbent assay (ELISA) weExpand
  • 11
  • 2
Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma.
Early results of a prospective phase 2 clinical trial of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide maintenance in high-risk smoldering myeloma showed promising resultsExpand
  • 17
  • 1